Ardelyx to Participate in Leerink Partners 7th Annual Global Healthcare Conference

FREMONT, Calif., Feb. 8, 2018 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX) today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference at 2:00 p.m. ET on Thursday, Feb. 15, 2018 in New York City.

To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the Investor section of the Ardelyx website at ir.ardelyx.com. A replay of the webcast will be available on the Ardelyx website for 60 days following the conference.

About Ardelyx, Inc.
Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing differentiated, minimally systemic medicines. Ardelyx's cardiorenal pipeline includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and RDX013, a potassium secretagogue program for the potential treatment of hyperkalemia. In addition to its cardiorenal pipeline, Ardelyx has completed Phase 3 development of tenapanor for the treatment of people with irritable bowel syndrome with constipation and anticipates submitting a New Drug Application to the U.S. Food and Drug Administration for this indication in the second half of 2018. To efficiently bring its treatments to market, Ardelyx is pursing strategic collaborations in the U.S. and beyond, with established agreements with Fosun Pharma in China and Kyowa Hakko Kirin in Japan. For more information, please visit http://www.ardelyx.com/ and connect with us on Twitter @Ardelyx.

View original content with multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-participate-in-leerink-partners-7th-annual-global-healthcare-conference-300595375.html

SOURCE Ardelyx

Monique Allaire, THRUST IR, 781-631-0759, monique@thrustir.com; Alicia Davis, THRUST IR, 910-620-3302, alicia@thrustir.com